Obsessive Compulsive Disorder and Its Care - A Review

  • Anjani Srivarsha Pratishta Institute of Pharmaceutical Sciences
  • D Sai Teja Pratishta Institute of Pharmaceutical Sciences
  • M Nagavamsidhar Pratishta Institute of Pharmaceutical Sciences
  • ZL Qadrie Pratishta Institute of Pharmaceutical Sciences
Keywords: OCD, Obsessive compulsive disorder, Tic disorder, Down syndrome, One-track mind, Fixation


Actually 14 to 16th century in Europe some people have experienced that sexual or other thoughts were by devil then the journey start. 1910, Sigmund Freud said that obsessions and compulsive behaviours are symptoms of OCD. Obsessive compulsory disorder (OCD) is an anxiety disorder. Obsessive compulsive disorder causes the brain stuck on a particular thought or urge. Actually these patients are having a obsessive thoughts means they always occurring of images, several thoughts or pictures over and over in the mind. These thoughts or rituals can triggered more anxiety. These OCD patients can find out by the facts like washing, cleaning, checking and repeating. The American psychiatric association said that the females are more affected then the men. The OCD is a common , chronic (long lasting disorder) the people with OCD can feel the temporary relief from the anxiety if the person can untreated then they cause the more stress and the effects seen on the work, school and lead to serious effects on personal relationships. Actually obsessive compulsive disorder is a brain injury , it involves basal ganglion (Eg: encephalitis or trauma) usually there is no neurologic precipitant. The evidence suggesting a selective and potent serotonin(5-HT) reuptake blocker drugs are successful treatment in biological basis of OCD. The drugs with the other mechanism of action have not been effective more. The neurotransmitter plays an important role in pathophysiology of obsessive compulsive disorder.

Author Biographies

Anjani Srivarsha, Pratishta Institute of Pharmaceutical Sciences

Department of Pharmacy Practice,
Pratishta Institute of Pharmaceutical Sciences,
Suryapet, Hyderabad, Telangana

D Sai Teja, Pratishta Institute of Pharmaceutical Sciences

Department of Pharmacy Practice,
Pratishta Institute of Pharmaceutical Sciences,
Suryapet, Hyderabad, Telangana

M Nagavamsidhar, Pratishta Institute of Pharmaceutical Sciences

Department of Pharmacy Practice,
Pratishta Institute of Pharmaceutical Sciences,
Suryapet, Hyderabad, Telangana

ZL Qadrie, Pratishta Institute of Pharmaceutical Sciences

Department of Pharmacy Practice,
Pratishta Institute of Pharmaceutical Sciences,
Suryapet, Hyderabad, Telangana


Aardema F, O’connor K (2007); The menace with in: obessions and the self; Journal of Cognitive Psychotherapy; 21(3); 182-197

Ab Boileau B (2011); A review of obsessive compulsive disorder in children and adolescents; Dialogues clin. neurosci; 13(4); 401-411.

Abramowitz js, Taylor S, Mckay D (2009); obsessive-compulsive disorder; Lancet; 374(9688); 491-499.

American psychiatric Association: - Diagnostic and statistical manual of mental disorders, 4th edition –Text revision. Washing ton, DC, USA. www.psychiatry.org/psychiatrists/practice/dsm

Angst I, Gamma A, Endrass I, Hantouche E, Good win R, Ajdacic V, EichD, Rossler W(2005); obsessive compulsive syndromes and disorders. Significance of comorbidity with bipolar and anxiety syndromes; Eur Arch psychiatary clin Neurosci; 255(1); 65-71

Barr LC, Goodman WK, Price LH, et al. (1992); The serotonin hypothesis of obsessive-compulsive disorder: implications of pharmacologic challenge studies; J Clin Psychiatry; 53(suppl 4); 17-28.

Baxter LR.(1995); Neuroimaging Studies of human anxiety disorders: Cutting paths of knowledge through the field of neurotic phenomena. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: Fourth Generation of progress. New York, Raven; 1287-1300.

Beecham Pharmaceuticals; Paxil Package insert; Philadelphia; 1998

beyondocd.org , information – for- parents/ helium. ping. a child –who-has-ocd.

Bland RC, Canino GJ, Weissman MM et al. (1994); The cross-national epidemiology of obsessive compulsive disorder. The cross national Collaborative Group; J Clin Psychiatry; 55 Suppl; 5-10.

Burch KJ, Wells, BG (1992); Fluoxetine/norfluoxetine concentration in human milk. Paediatrics ; 89(4); 676-677.

Ciba-Geigy. Anafranil package insert. Summit NJ, 1998.

Clomipramine collaborative study group (1991); Clomipramine in the treatment of patients with obsessive-compulsive disorder; Arch Gen psychiatry; 48(8); 730-738

Diagnostic and statistical manual of mental disorders: DSM-5 (5. ed). Washington: American psychiatric publishing.2013. Pp.237-242 www.psychiatry.org

Diaz SF, Grush LR, Sichel DA, Cohen LS; Obsessive compulsive disorder in pregnancy and the puerperium. In: Pato MT, Steketee G, eds. OCD Across the life cycle. Section 123 of review of Psychiatry vol-16. Washington, DC, American Psychiatric press,1997; 97-112.

Dista Products. Prozac Package insert. Indianapolis, 2000

Forest laboratories, Inc. Celexa package insert. St. Louis, MO, 2000.

Gary S. Sachs, M.D (1997); Expert Consensus Panel for obsessive compulsive disorder. obsessive compulsive disorder executive summary: Recommendations for first line treatments by clinical situations; J Clin Psychiatry ; 58 (suppl 4); 11-12.

Germana Moretti et al. (2008); What every psychiatrist should know about PANDAS: a review; Clinical practise and epidemiology in Mental health; 4; 13

Gold stein DJ (1995); Effects of third trimester fluoxetine exposure on the new born; J Clin Psychopharmacol; 15(6); 417-420.

Greist JH, Jefferson JW, Kobhan KA, et al. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. Arch Gen psychiatry 1995; 52(1); 53-60 .

Hollander E, DeCaria CM, Nitescu A, et al.(1992); Serotonergic function in obsessive-compulsive disorder: Behavioural and neuroendocrine responses to oral m-chlorophenyl piperazine and fenfluramine in patients and healthy volunteers. Arch Gen psychiatry; 53(suppl-4); 17-28.








https://www.Ocduk.Org/types - ocd .

Jenike MA (2004); Clinical practice. Obsessive compulsive disorder; N Engl. J. Med.; 350(3); 259-265.

Kessler RC, Chiu WT, Demler O, et al (2005); prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication; Arch Gen Psychiatry; 62(6); 617-627

Koponen H, Lepola U, Leinonen E, et al (1997); Citalopram in the treatment of obsessive compulsive disorder: An open pilot study. Acta PsychiatrScand; 96(5); 343-346.

Lysaker Ph, Bryson GJ, Marks KA, Greig TC, Bell MD (2000); Association of obsessions and compulsions in schizophrenia with neuro cognition and negative symptoms; J neuropsychiatry clin neurosci.; 14(4); 449-453

Maria Laura Bianchi, Paolo Cavedini, Stefano Erzegovesi, Laura Bellodi, (1997); Relationship between obsessive-compulsive personality disorder and obsessive-compulsive disorder; Comprehensive Psychiatry; 38(1); 38-42

McDougle CJ, Goodman WK, Price LH. (1994); Dopamine antagonists in tic related and Psychotic spectrum obsessive compulsive disorder; J clin pstchiatry; 55(suppl 3); 24-31.

Montgomery S, Kasper S, Bang-Hedegaard K, Lundbeck H. The SSRI citalopram is effective in the obsessive-compulsive disorder: Results from a double-blind, fixed dose, placebo-controlled trail. Presented at the Annual meeting of the American psychiatric Association, Chicago, IL, May 13-18, 2000.

Pastuszak A, Schick- Poschetto B, Zuber C, et al. (1993); Pregnanacy outcome following first trimester exposure to fluoxetine (Prozac); JAMA ; 269(17); 2246-2248.

Pato MT, Pato CN. (1997); obsessive-compulsive disorder in adult’s life. IN: Pato MT, Steketee G, eds. OCD Across the Life cycle. Section III Review of psychiatry, vol 16. Washington, DC, American Psychiatric Press; 30-55.

Pfizer. Zoloft package insert. New York, 2000

Robertson MM, Yakeley J. Gilles de la (1996); Tourette syndrome and obsessive-compulsive disorder. In: Fogel BS, Schiffer RB, eds. Neuropsychiatry, Baltimore, Williams & Wilkins, 827-870

Ruscio AM, Stein DJ, Chiu WT, Kessler RC(2010); The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication; Mol Psychiatry; 15(1); 53-63

Solvay Pharmaceuticals. Luvox package insert. Marietta, GA, 1998.

Stein DJ, Lochner L (2006); Obsessive-compulsive spectrum disorders: a multidimensional approach; The psychiatric clinics of North America; 29(2); 343-351

Taddio A (1996); Excretion of fluoxetine and its metabolite, norfluoxetine, in human breast milk; J Clin Pharmacol; 36(1); 42-47.

The National Institute of Mental Health (NIMH). “(jan 2010).” What is ocd”? U.S National institute of health (NIH). https://www.nimh.nih.gov/health/topics/obsessive-compulsive-disorder-ocd/what-is-ocd.shtml



www.mayoclinic.org/ diseases –conditions /obsessive-compulsive-disorder /symptoms- causes/ dxc-20245951/

www.psychguides.com/guides/obsessive-compulsive disorder-symptoms-causes-and effects.

www.webmd.Com / mental health/ obsessive compulsive disorder.

How to Cite
Srivarsha, A., Sai Teja, D., Nagavamsidhar, M. and Qadrie, Z. 2018. Obsessive Compulsive Disorder and Its Care - A Review. PharmaTutor. 6, 12 (Dec. 2018), 1-9. DOI:https://doi.org/10.29161/PT.v6.i12.2018.1.

Most read articles by the same author(s)